Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.

Next Previous
Trial Profile

Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Salmeterol (Primary) ; Fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics

Most Recent Events

  • 07 Dec 2022 Results (n=46) assessing whether gene expression signatures obtained in asthma can be used to identify the subgroup of patients with COPD with steroid sensitivity published in the Thorax
  • 09 Nov 2009 New trial record.
  • 20 Oct 2009 Results were reported in the Annals of Internal Medicine.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top